旁中央急性中层黄斑病变与视盘周围积液联合作为前部缺血性视神经病变生物标志物
一项嵌套前瞻性横断面诊断准确性研究,纳入8例动脉炎性前部缺血性视神经病变(A-AION)和24例非动脉炎性AION(NA-AION)患者,评估旁中央急性中层黄斑病变(PAMM)和视盘周围视网膜内/视网膜下积液(IRF/SRF)能否早期区分两型。PAMM见于50%A-AION和0%NA-AION(P=0.0019),中央黄斑区IRF/SRF见于83%NA-AION和0%A-AION(P=0.000047),联合两种生物标志物可仅基于OCT对75%AION进行分类。
要点
- PAMM对A-AION诊断灵敏度50%(95%CI 16%-84%),特异度100%(95%CI 86%-100%)。
- 累及中央黄斑的IRF/SRF对NA-AION诊断灵敏度83%(95%CI 63%-95%),特异度100%(95%CI 63%-100%)。
- 联合PAMM与IRF/SRF两种OCT生物标志物,75%AION患者可仅基于OCT分类。
核心结论
- PAMM似乎是A-AION的生物标志物,而广泛的视盘周围积液似乎是NA-AION的生物标志物。
- 联合OCT生物标志物可能有助于AION的早期分类,并需进一步前瞻性研究。
研究设计与样本
- 嵌套前瞻性横断面诊断准确性研究,采用单中心OCT数据,纳入8例A-AION和24例NA-AION患者,来自两项连续采样的前瞻性横断面研究(ClinicalTrials.gov: NCT05248906和NCT05305079)。
- A-AION诊断基于炎症生化标志物的专家判读、颞动脉活检和正电子发射断层扫描/计算机断层扫描;NA-AION诊断基于无A-AION可疑或临床证据且经神经眼科专家确诊。
- 本亚组研究要求患者有与AION诊断相关的OCT扫描,黄斑OCT扫描由两名独立设盲的评分者判读PAMM和IRF/SRF,IRF/SRF范围采用早期糖尿病视网膜病变治疗研究(ETDRS)网格评估。
主要发现
- PAMM见于50%A-AION患者和0%NA-AION患者(P=0.0019)。
- 在AION背景下,PAMM诊断A-AION的灵敏度为50%(95%CI 16%-84%),特异度为100%(95%CI 86%-100%)。
- 视盘周围IRF/SRF延伸进入ETDRS网格见于83%NA-AION患者和0%A-AION患者(P=0.000047)。
- 累及中央黄斑的IRF/SRF诊断NA-AION的灵敏度为83%(95%CI 63%-95%),特异度为100%(95%CI 63%-100%)。
- 联合两种生物标志物,75%AION患者可仅基于OCT进行分类。
关键数值与推荐
- PAMM诊断A-AION:灵敏度50%(95%CI 16%-84%),特异度100%(95%CI 86%-100%)。
- 累及中央黄斑的IRF/SRF诊断NA-AION:灵敏度83%(95%CI 63%-95%),特异度100%(95%CI 63%-100%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出联合OCT生物标志物可能有助于AION早期分类,并需进一步前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine if paracentral acute middle maculopathy (PAMM) and peripapillary intraretinal and subretinal fluid (IRF/SRF) could help distinguish between arteritic anterior ischemic optic neuropathy (A-AION) and nonarteritic AION (NA-AION) at an early stage. DESIGN: Nested prospective cross-sectional diagnostic accuracy study. METHODS: This study used single-center optical coherence tomography (OCT) data from 8 patients with A-AION and 24 patients with NA-AION from two prospective cross-sectional studies with consecutive sampling (ClinicalTrials.gov: NCT05248906 and NCT05305079). The diagnosis of A-AION was based on expert interpretation of biochemical markers of inflammation, temporal artery biopsy and positron emission tomography/computed tomography. The diagnosis of NA-AION was made in cases without suspicion or clinical evidence of A-AION and with confirmed neuroophthalmological expert diagnosis. For this substudy patients were also required to have an OCT scan in relation to the diagnosis of AION. Macular OCT scans were graded by two independent, masked graders for the presence of PAMM and for IRF/SRF. The extension of IRF/SRF was assessed using an Early Treatment Diabetic Retinopathy Study (ETDRS) grid. RESULTS: PAMM was found in 50% of patients with A-AION and in 0% of patients with NA-AION (P = .0019). In the setting of AION, the sensitivity of PAMM for the diagnosis of A-AION was 50% (95% CI: 16%-84%) while the specificity was 100% (95% CI: 86%-100%). Conversely, peripapillary IRF/SRF with extension into the ETDRS grid was observed in 83% of patients with NA-AION but in 0% of patients with A-AION (P = .000047). The sensitivity of central macula-involving IRF/SRF for the diagnosis of NA-AION was 83% (95% CI: 63%-95%), while the specificity was 100% (95% CI: 63%-100%). Combining the two biomarkers, 75% of patients with AION could be classified based on OCT alone. CONCLUSION: PAMM appears to be a biomarker of A-AION while extensive peripapillary fluid appears to be a biomarker of NA-AION. Combining OCT biomarkers might allow for early classification of AION and warrants further prospective studies.
引用
- Klefter ON, Hansen MS, Lykkebirk L, et al. Combining Paracentral Acute Middle Maculopathy and Peripapillary Fluid as Biomarkers in Anterior Ischemic Optic Neuropathy. Am J Ophthalmol. 2024. PMID: 39645178. doi:10.1016/j.ajo.2024.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。